Alnylam Pharmaceuticals (NASDAQ:ALNY) Reaches New 52-Week Low at $142.14

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) reached a new 52-week low during trading on Thursday . The company traded as low as $142.14 and last traded at $143.25, with a volume of 45496 shares traded. The stock had previously closed at $143.80.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on ALNY. BMO Capital Markets restated an “outperform” rating and set a $234.00 price target on shares of Alnylam Pharmaceuticals in a research note on Wednesday, March 27th. HC Wainwright reiterated a “buy” rating and set a $395.00 price target on shares of Alnylam Pharmaceuticals in a research report on Tuesday, March 5th. JPMorgan Chase & Co. lifted their price objective on Alnylam Pharmaceuticals from $150.00 to $170.00 and gave the company a “neutral” rating in a research report on Thursday, February 1st. Chardan Capital lowered their target price on shares of Alnylam Pharmaceuticals from $250.00 to $225.00 and set a “buy” rating on the stock in a research note on Friday, February 16th. Finally, Wells Fargo & Company dropped their price target on Alnylam Pharmaceuticals from $171.00 to $161.00 and set an “equal weight” rating for the company in a research report on Friday, February 16th. Nine investment analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat.com, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $216.12.

Alnylam Pharmaceuticals Stock Performance

The company has a market cap of $18.22 billion, a price-to-earnings ratio of -40.05 and a beta of 0.39. The company’s 50 day moving average price is $150.36 and its 200 day moving average price is $166.12.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.20) by $0.10. The firm had revenue of $439.72 million for the quarter, compared to the consensus estimate of $439.38 million. The company’s revenue was up 31.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($1.68) earnings per share. On average, equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -4.46 EPS for the current fiscal year.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the business. Allspring Global Investments Holdings LLC raised its stake in Alnylam Pharmaceuticals by 572.0% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 143 shares during the period. Quent Capital LLC raised its stake in shares of Alnylam Pharmaceuticals by 246.0% in the fourth quarter. Quent Capital LLC now owns 173 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 123 shares during the period. Anchor Investment Management LLC bought a new stake in Alnylam Pharmaceuticals in the 4th quarter valued at about $38,000. Robeco Institutional Asset Management B.V. lifted its stake in shares of Alnylam Pharmaceuticals by 155.7% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 20,549 shares of the biopharmaceutical company’s stock valued at $39,000 after buying an additional 12,513 shares in the last quarter. Finally, GAMMA Investing LLC bought a new position in Alnylam Pharmaceuticals in the 4th quarter worth approximately $52,000. 92.97% of the stock is currently owned by institutional investors and hedge funds.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.